Baxter International Inc. — FY2020 Form 10-K
Reporting period: Fiscal year ended December 31, 2020. This is an annual filing, not a standalone fourth-quarter report. Amounts are in U.S. dollars; financial amounts are generally in millions unless stated otherwise.
Business context
Baxter sells essential medical products and therapies, including dialysis, IV solutions and infusion systems, injectable pharmaceuticals, nutrition products, and surgical sealants. It reports through the Americas, EMEA, and APAC segments. The filing describes COVID-19 as an ongoing source of operational, demand, supply-chain, and cost disruption.
Key financial results
| Metric | FY2020 | FY2019 | Change or context |
|---|---|---|---|
| Net sales | $11,673 | $11,362 | Up 3% reported and at constant currency |
| Gross margin | $4,587; 39.3% | $4,761; 41.9% | Margin down 2.6 percentage points |
| Operating income | $1,616 | $1,772 | Down about 9% |
| Income from continuing operations | $1,110 | $1,011 | Up about 10% |
| Diluted EPS from continuing operations | $2.13 | $1.93 | Up about 10% |
| Operating cash flow, continuing operations | $1,870 | $2,110 | Down $240 |
| Capital expenditures | $709 | $696 | Cash flow less capital expenditures was about $1,161 |
| Cash and cash equivalents | $3,730 | $3,335 | At year-end |
| Total debt and finance lease obligations | $6,192 | $5,124 | Includes current maturities |
SG&A was $2,469 (21.2% of sales), versus $2,535 (22.3%) in 2019. R&D was $521 (4.5% of sales), versus $595 (5.2%). The effective tax rate was 14.1%, compared with a benefit-rate of 4.2% in 2019. The company declared dividends of $0.955 per share in 2020 and repurchased approximately 6.3 million shares for $500 million.
Fourth-quarter 2020 sales were $3,181, and net income attributable to Baxter stockholders was $168; diluted EPS was $0.33. Fourth-quarter results included charges for debt extinguishment, infusion-pump remediation, and pension settlements.
Material changes and operating drivers
- Sales growth was led by Acute Therapies, up 38% (including demand for CRRT systems during COVID-19), and Clinical Nutrition, up 6%. Renal Care grew 3%.
- Medication Delivery sales fell 2%, mainly from reduced hospital admissions and elective procedures. Pharmaceuticals sales fell 1%, including lower inhaled-anesthesia demand and competition. Advanced Surgery grew 1%, with the Seprafilm acquisition contributing $94 in sales.
- COVID-19 reduced demand in some procedure-sensitive categories and increased employee compensation, logistics costs, and manufacturing inefficiencies. Management said these factors contributed to lower gross margin.
- Operating cash flow declined partly because of $173 in payments to settle interest-rate derivative contracts, increased inventory, and insurance recoveries received in 2019.
- FY2020 continuing-operations income included special items that management said reduced income by a net $495, or $0.96 per diluted share. Items included $222 of intangible amortization, $134 of business-optimization costs, a $110 debt-extinguishment loss, and pension settlement charges.
Liquidity, debt, outlook, and risks
- At year-end, Baxter had $3.7 billion cash and no borrowings under its $2.0 billion U.S. revolving facility or approximately €200 million Euro facility, both maturing in 2024. It reported compliance with financial covenants and stable credit-rating outlooks.
- Management expected a 2021 GAAP effective tax rate of approximately 18% and capital expenditures to increase, including potential multi-year investment in peritoneal-dialysis capacity in response to U.S. kidney-care payment-model changes. No specific 2021 revenue or EPS guidance is provided in the filing text.
- Management reported that approximately 95% of expected annual pre-tax savings from its optimization initiatives had been realized by year-end; it expects the remainder by the end of 2023. Remaining costs for initiatives then underway were estimated at approximately $14.
- COVID-19 risks include unpredictable changes in demand, supply disruption, delayed customer payments, workforce constraints, and cybersecurity exposure. Baxter specifically reported constraints on amino-acid raw materials used in parenteral nutrition products.
- Other notable risks include regulatory and product-quality matters, pricing and reimbursement pressure, foreign-exchange exposure, and litigation. The Ahmedabad, India facility remained subject to an FDA Warning Letter; management said it could not predict when it would be lifted. Mountain Home, Arkansas, ethylene-oxide emissions controls were being upgraded, with an additional $40 of capital spending expected and completion anticipated in 2022.
- Baxter disclosed a prior restatement involving foreign-exchange accounting. Management said the related material weakness had been remediated as of December 31, 2020; the auditor opined that financial statements were fairly presented and internal control over financial reporting was effective. The company continued cooperating with the SEC, and related shareholder litigation remained a matter to monitor.
Important facts for investors to verify
- Whether COVID-19-related procedure volumes, demand patterns, supply constraints, and added costs improve or worsen, particularly their effect on gross margin.
- Progress against the 2021 tax-rate outlook, increased capital spending, and the capacity and demand assumptions underlying kidney-care investment plans.
- Debt maturities, financing costs, and cash generation after capital expenditures, dividends, and share repurchases.
- Developments in the FDA Warning Letter, Mountain Home emissions-control project, infusion-pump remediation, and other product-quality or regulatory matters.
- Any further developments in the SEC inquiry or litigation connected with the prior financial-statement restatement, and continued effectiveness of the remediated controls.
- Completion terms and expected returns for announced acquisitions, including the Caelyx/Doxil and Transderm Scop transactions, which were pending at the filing date.